Malignant melanoma of unknown primary site in patient with pustulosis plantaris

• Authors: Brzeziński Piotr , Ahmad Abdulaziz , Jacek Andruszkiewicz , Anca Chiriac
• Languages of publication: EN

Abstracts

EN

We reported a 57 year old woman treated for 2 years because of pustulosis plantaris (periodic exacerbations and remissions). In July 2013 she reported to the Outpatient Surgery because of a tumor in the left groin area. The biopsy revealed: metastases melanomatosis in lymphonodus. The patients was in October at the surgical removal of lymph nodes from left groin area (lymphadenectomy groin - ilio - obturatorii right). Full diagnostic was carried out and searching of of primary foci to no results. In the patient revealed the presence of BRAF and she was qualified to study of drug vemurafenib.

Keywords

EN

BRAF inhibitors; lymph node; malignant melanoma; metastasis; pustulosis plantaris; vemurafenib

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2014
• Volume: 4
• Issue: 2
• Pages: A69-71

Contributors

author

Brzeziński Piotr

• Military Ambulatory, 6th Military Support Unit

author

Ahmad Abdulaziz

• Department of General Surgery, District Hospital, Iława, Poland

author

Jacek Andruszkiewicz

• Clinical Department of Surgical Oncology, Prof. Francis Łukaszczyk Oncology Center, Bydgoszcz, Poland

author

Anca Chiriac

• Department of Dermato-Physiology, Apollonia University Iasi, Strada Muzicii nr 2, Iasi Romania

References

• Drljevic I, Drljevic K. Dermoscopy of head melanoma-case studies and review of references. Our Dermatol Online 2012; 3: 123-125.
• Abdulaziz A, Andruszkiewicz J, Brzezinski P. In anticipation of the biopsy. Tumor on the leg. Our Dermatol Online 2014; 5: e1.
• Kamposioras K, Pentheroudakis G, Pectasides D et al. Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit Rev Oncol Hematol 2011; 78: 112-126.
• Gadiot J, Hooijkaas AI, Deken MA et al. Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity. Onco Targets Ther 2013; 6: 1649-58.
• Blessing K, McLaren KM. Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology 1992; 20: 315-322.

• Document Type: undetermined